- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07680049
The Mediating Role of Balance in the Relationship Between Fatigue and Fear of Falling in Individuals With Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disease of the central nervous system that frequently leads to fatigue, balance impairment, and fear of falling. These symptoms negatively affect mobility, independence, participation in daily activities, and quality of life. Fatigue is one of the most common and disabling symptoms in individuals with MS and may contribute to impaired balance and an increased risk of falls.
Fear of falling is highly prevalent in people with MS and is associated with reduced physical activity, activity avoidance, and functional decline. Balance impairment is another common manifestation of MS and may represent an important mechanism linking fatigue to fear of falling. However, although fatigue, balance, and fear of falling have been investigated separately, the mediating role of balance in the relationship between fatigue and fear of falling has not been sufficiently explored.
The aim of this cross-sectional observational study is to investigate whether balance mediates the relationship between fatigue and fear of falling in individuals with multiple sclerosis. Fatigue will be assessed using the Fatigue Severity Scale (FSS), balance performance will be evaluated using the Mini-Balance Evaluation Systems Test (Mini-BESTest), and fear of falling will be measured using the Falls Efficacy Scale-International (FES-I).
The findings of this study are expected to improve the understanding of the mechanisms underlying fear of falling in individuals with MS and provide evidence to support the development of rehabilitation programs targeting balance to reduce fear of falling and improve functional outcomes.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: osman çoban, phD
- Phone Number: 00905337242919
- Email: osman.coban@uskudar.edu.tr
Study Contact Backup
- Name: Günay çimen aysal, phd
- Phone Number: 00905336425822
- Email: gnycimen@gmail.com
Study Locations
-
-
Üsküdar
-
Istanbul, Üsküdar, Turkey (Türkiye), 34662
- Uskudar University
-
Contact:
- Günay çimen aysal, phd
- Phone Number: 00905336425822
- Email: gnycimen@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18-65 years
- Neurologist-confirmed MS diagnosis
- No relapse within the previous 30 days
- Ability to walk independently or with an assistive device
- Ability to understand instructions
- Voluntary participation
Exclusion Criteria:
- Recent MS relapse
- Severe vestibular disorder
- Other neurological diseases
- Severe orthopedic conditions affecting mobility
- Recent lower extremity surgery or trauma
- Cardiopulmonary conditions limiting assessment
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Individuals with Multiple Sclerosis
Adults diagnosed with multiple sclerosis who meet the eligibility criteria will participate in a single assessment session to evaluate fatigue, balance, and fear of falling.
|
Observational Model: Cross-Sectional
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Falls Efficacy Scale-International
Time Frame: Time Frame: Baseline (single assessment)
|
Fear of falling will be assessed using the Falls Efficacy Scale-International (FES-I).
The FES-I is a 16-item questionnaire that evaluates concern about falling during a range of daily activities.
Total scores range from 16 to 64, with higher scores indicating greater fear of falling.
|
Time Frame: Baseline (single assessment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fatigue Severity Scale (FSS)
Time Frame: Baseline (single assessment)
|
Fatigue severity will be assessed using the Fatigue Severity Scale (FSS).
The FSS consists of 9 items rated on a 7-point Likert scale.
The total score is calculated as the mean of all items, with higher scores indicating greater fatigue severity.
|
Baseline (single assessment)
|
|
Baseline (single assessment)
Time Frame: Baseline (single assessment)
|
Balance performance will be evaluated using the Mini-Balance Evaluation Systems Test (Mini-BESTest).
The Mini-BESTest consists of 14 items assessing dynamic balance.
Total scores range from 0 to 28, with higher scores indicating better balance performance.
|
Baseline (single assessment)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler. 2003 Jun;9(3):219-27. doi: 10.1191/1352458503ms904oa.
- Nilsagard Y, Lundholm C, Denison E, Gunnarsson LG. Predicting accidental falls in people with multiple sclerosis -- a longitudinal study. Clin Rehabil. 2009 Mar;23(3):259-69. doi: 10.1177/0269215508095087.
- Hebert JR, Corboy JR. The association between multiple sclerosis-related fatigue and balance as a function of central sensory integration. Gait Posture. 2013 May;38(1):37-42. doi: 10.1016/j.gaitpost.2012.10.015. Epub 2012 Nov 28.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Uskudar-MS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
Cabaletta BioWithdrawnProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; University of Copenhagen and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
Clinical Trials on Observational Model: Cross-Sectional
-
Cairo UniversityCompleted
-
CalydialCompletedHemodialysis | DIALYSIS SYMPTOMS AND ANXIETYFrance
-
University Hospital, GhentUniversity GhentCompletedOverweight and ObesityBelgium
-
Hong Kong Baptist UniversityCompletedDiabetes Mellitus, Type 2 | Metabolic SyndromeHong Kong
-
Oğuzhan KandemirRecruitingFibromyalgia Syndrome | ChronotypeTurkey
-
Modum BadUniversity of OsloCompletedLoneliness, Worry, Rumination, Health Anxiety, Depression, AnxietyNorway
-
Ahram Canadian UniversityRecruiting
-
University of PecsRecruitingQuality of Life | Colorectal Cancer | Anal Cancer | Fecal Incontinence | Physical InactivityHungary
-
Istanbul Medipol University HospitalCompletedIdiopathic Pulmonary FibrosisTurkey
-
University Hospital, GrenobleUnknown